Compare General Dynamics Corporation (GD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Organon & Co. Common Stock — how do they compare? General Dynamics Corporation trades at $338.85 (market cap $89.94B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: General Dynamics Corporation is far larger — about 24.8× Organon & Co. Common Stock's market cap, and General Dynamics Corporation pays the higher dividend (1.91%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 86 Days and Organon & Co. Common Stock for 0 Days on average.
| GD | OGN | |
|---|---|---|
Market Cap | $89.94B | $3.62B |
Volume | 1,284,020 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $395.97 | $13.81 |
52-Week Low | $312.53 | $5.70 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $95.08B | $11.04B |
Dividend Yield | 1.91% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $334.66, down 0.24% with bearish technical signals despite strong fundamentals. The defense contractor shows robust revenue growth, increasing from $47.7B in 2024 to $52.5B in 2025, with consistent earnings beats. Analyst consensus remains bullish with a $414.57 price target, supported by strong Pentagon spending and dividend stability.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.27) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend champion status provide downside protection. Upside potential exists if technical resistance at $337 is breached.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
